Skip to main content
Clinical Trials/NCT01234155
NCT01234155
Completed
Not Applicable

Exercise Training and Type 2 Diabetes

Rigshospitalet, Denmark1 site in 1 country32 target enrollmentAugust 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 2
Sponsor
Rigshospitalet, Denmark
Enrollment
32
Locations
1
Primary Endpoint
Glycemic Control
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to assess whether 4-months of interval-walking exercise training improves glycemic control in individuals with type 2 diabetes mellitus. The effects of interval-walking training will be compared to continuous-walking exercise in a randomised, controlled trial design. Changes in glycemic control will be examined using oral glucose tolerance tests (OGTT) with stable isotope methodology. In addition, insulin sensitivity and secretion will be examined using glucose clamps combined with glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Registry
clinicaltrials.gov
Start Date
August 2010
End Date
November 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Thomas Solomon

Group Leader

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • age 18 to 80
  • normal glucose tolerance, impaired glucose tolerance, or type 2 diabetes (as evidenced by use of oral hypoglycemic medication or 2-hour OGTT glucose \> 11.1 mmol/l)

Exclusion Criteria

  • Insulin treatment or type 1 diabetes
  • BMI \<19 or \>40
  • Physically active
  • Undergoing weight-loss/gain
  • Pregnancy
  • Contraindication to exercise (ECG/CPX)
  • Significant cardiovascular disease
  • History of renal/hepatic/gastrointestinal/pulmonary disease
  • Clotting or bleeding disorders

Outcomes

Primary Outcomes

Glycemic Control

Time Frame: 0 and 4 months

Fasting glucose, two-hour glucose during OGTT, and hemoglobin A1c will be measured.

Secondary Outcomes

  • Beta-cell Function(0 and 4 months)
  • Body Composition(0 and 4 months)

Study Sites (1)

Loading locations...

Similar Trials